This source provides a comprehensive overview of Johnson & Johnson's (J&J) financial performance for the third quarter of 2025, emphasizing the strength and depth of its portfolio across two primary segments: Innovative Medicine and MedTech. The report details quarterly sales figures and operational growth for both segments, while also highlighting the impact of factors like the decline of Stelara due to biosimilar competition and the redesign of Part D. Furthermore, the document outlines J&J's strategic focus areas in healthcare, lists key innovative products and pipeline updates in Oncology, Immunology, Neuroscience, and MedTech, and mentions the company's intent to separate its Orthopaedics business and provides updated financial guidance for 2025.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
13:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
10:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
13:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana